Hwang Seung Rim, Chakraborty Kushal, An Jeong Man, Mondal Jagannath, Yoon Hong Yeol, Lee Yong-Kyu
College of Pharmacy, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Korea.
Department of IT and Energy Convergence (BK21 FOUR), Korea National University of Transportation, Chungju 27469, Korea.
Pharmaceutics. 2021 Nov 5;13(11):1875. doi: 10.3390/pharmaceutics13111875.
Drug delivery to tumor sites using nanotechnology has been demonstrated to overcome the drawbacks of conventional anticancer drugs. Altering the surface shape and geometry of nanocomposites alters their chemical properties, which can confer multiple attributes to nanocarriers for the treatment of cancer and their use as imaging agents for cancer diagnosis. However, heterogeneity and blood flow in human cancer limit the distribution of nanoparticles at the site of tumor tisues. For targeted delivery and controlled release of drug molecules in harsh tumor microenvironments, smart nanocarriers combined with various stimuli-responsive materials have been developed. In this review, we describe nanomaterials for smart anticancer therapy as well as their pharmaceutical aspects including pharmaceutical process, formulation, controlled drug release, drug targetability, and pharmacokinetic or pharmacodynamic profiles of smart nanocarriers. Inorganic or organic-inorganic hybrid nanoplatforms and the electrospinning process have also been briefly described here.
利用纳米技术将药物递送至肿瘤部位已被证明可以克服传统抗癌药物的缺点。改变纳米复合材料的表面形状和几何结构会改变其化学性质，这可为纳米载体赋予多种特性，用于癌症治疗以及作为癌症诊断的成像剂。然而，人类癌症中的异质性和血流限制了纳米颗粒在肿瘤组织部位的分布。为了在恶劣的肿瘤微环境中实现药物分子的靶向递送和控释，已开发出与各种刺激响应材料相结合的智能纳米载体。在这篇综述中，我们描述了用于智能抗癌治疗的纳米材料及其药学方面，包括制药工艺、制剂、药物控释、药物靶向性以及智能纳米载体的药代动力学或药效学概况。本文还简要介绍了无机或有机-无机杂化纳米平台以及静电纺丝工艺。
